Affimed (AFMD) is pioneering a transformative innate immunity therapeutic approach to eradicating solid and hematologic tumors to help patients fight cancer.
Location: Czechia, Prague
Total raised: $46.58M
Investors 2
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Perceptive... | perceptive... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.10.2012 | Series D | $19.96M | - |
| 30.04.2010 | Series C | $26.61M | - |
Mentions in press and media 13
| Date | Title | Description | Source |
| 06.03.2024 | Affimed Announces 1-for-10 Reverse Stock Split | - | globenewsw... |
| 23.05.2023 | Affimed Reports First Quarter 2023 Financial Results and Hig... | AFM13 combination with AB-101 NK cells: Received IND clearance from the FDA for a phase 2 clinical t... | einpresswi... |
| 12.04.2022 | Affimed Announces Pricing of Upsized $90 Million Public Offe... | HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or th... | globenewsw... |
| 02.03.2022 | Fast-Growing German Biotech Affimed Chooses Generis CARA™ Li... | The CARA platform from Generis offers us unique potential to enter information and re-use it across ... | prweb.com/... |
| 09.12.2021 | Affimed N : Press Release dated December 9, 2021 - Form 6-K | PRESS RELEASE Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymp... | marketscre... |
| 09.12.2021 | Affimed to Host Virtual Investor Call Today to Discuss Treat... | For the 13 patients treated at the recommended phase 2 dose (RP2D) the response rate after one cycle... | marketscre... |
| 22.11.2021 | Affimed N : Announces 100% Objective Response Rate at Highes... | Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-deri... | marketscre... |
| 11.11.2021 | Affimed Reports Third Quarter 2021 Financial Results and Hig... | Heidelberg, Germany - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committe... | marketscre... |
| 20.05.2021 | AFFIMED N.V. Press Release : Affimed Announces Virtual Annu... | Heidelberg, Germany, May 20, 2021 -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology c... | marketscre... |
| 09.04.2021 | AFFIMED N.V. Press Release : Affimed Announces Presentation... | -- All four patients experienced significant disease reduction, with two complete responses and two ... | marketscre... |
Show more